Last reviewed · How we verify
WR826647
At a glance
| Generic name | WR826647 |
|---|---|
| Also known as | Triazine WR826647 |
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WR826647 CI brief — competitive landscape report
- WR826647 updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI